Compounds > n(6)-(2,2-diphenylethyl)adenosine

Page last updated: 2024-11-12

n(6)-(2,2-diphenylethyl)adenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N(6)-(2,2-diphenylethyl)adenosine: adenosine receptor agonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	10388920
CHEMBL ID	193692
SCHEMBL ID	6852543
MeSH ID	M0152250

Synonyms (23)

Synonym
adenosine, n-(2,2-diphenylethyl)-
n-(2,2-diphenylethyl)adenosine
ci 936
brn 6020899
ci-936
bdbm50163015
(2r,3r,4s,5r)-2-[6-(2,2-diphenyl-ethylamino)-purin-9-yl]-5-hydroxymethyl-tetrahydro-furan-3,4-diol
CHEMBL193692 ,
mrs-3310
98383-40-5
n(6)-(2,2-diphenylethyl)adenosine
ej0e2og5j5 ,
unii-ej0e2og5j5
SCHEMBL6852543
TUGMXIURLRAWSS-UMCMBGNQSA-N
n6 -(2,2-diphenylethyl)adenosine
n-(2,2-diphenylethyl)-adenosine
n6-(2,2-diphenylethyl)adenosine
n6-(2,2-diphenylethyl)-adenosine
(2r,3r,4s,5r)-2-[6-(2,2-diphenylethylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
AKOS034804525
PD161801
Z1980939584

Research Excerpts

Toxicity

Excerpt	Reference	Relevance
" These studies demonstrated that DPEA produced a range of adverse effects in common laboratory animal species."	( Preclinical toxicity studies of an adenosine agonist, N-(2,2-diphenylethyl) adenosine. Barsoum, NJ; Macallum, GE; Smith, GS; Walker, RM, 1991)	0.28

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (8)

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Adenosine receptor A3	Homo sapiens (human)	Ki	0.0039	0.0000	0.9306	10.0000	AID239092; AID706384
Adenosine receptor A1	Rattus norvegicus (Norway rat)	Ki	0.0142	0.0001	1.2092	9.9700	AID32015; AID32177; AID32503; AID706387
Adenosine receptor A3	Rattus norvegicus (Norway rat)	Ki	0.5390	0.0003	0.9196	9.0000	AID239053; AID706385
Adenosine receptor A2a	Homo sapiens (human)	Ki	0.3950	0.0000	1.0609	9.7920	AID1694570; AID239113; AID647885; AID706388
Adenosine receptor A2b	Rattus norvegicus (Norway rat)	Ki	0.0250	0.0006	1.3536	10.0000	AID33440; AID33733
Adenosine receptor A1	Homo sapiens (human)	Ki	0.0500	0.0002	0.9316	10.0000	AID1694569; AID239011; AID706386
Adenosine receptor A2a	Rattus norvegicus (Norway rat)	Ki	0.0417	0.0002	1.4940	10.0000	AID33440; AID33733; AID706389
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Adenosine receptor A2b	Homo sapiens (human)	EC50 (µMol)	0.4850	0.0003	0.9461	10.0000	AID1694572
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Adenosine receptor A1	Rattus norvegicus (Norway rat)	EC25 (µMol)	0.0100	0.0030	0.0142	0.0350	AID175310
Adenosine receptor A2b	Rattus norvegicus (Norway rat)	EC25 (µMol)	0.0100	0.0030	0.0142	0.0350	AID175310
Adenosine receptor A2b	Rattus norvegicus (Norway rat)	Ratio	0.0250	0.0033	0.8292	9.6000	AID33746
Adenosine receptor A2a	Rattus norvegicus (Norway rat)	EC25 (µMol)	0.0100	0.0030	0.0142	0.0350	AID175310
Adenosine receptor A2a	Rattus norvegicus (Norway rat)	Ratio	0.0250	0.0033	0.8230	9.6000	AID33746
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (105)

Process	via Protein(s)	Taxonomy
inflammatory response	Adenosine receptor A3	Homo sapiens (human)
signal transduction	Adenosine receptor A3	Homo sapiens (human)
activation of adenylate cyclase activity	Adenosine receptor A3	Homo sapiens (human)
regulation of heart contraction	Adenosine receptor A3	Homo sapiens (human)
negative regulation of cell population proliferation	Adenosine receptor A3	Homo sapiens (human)
response to wounding	Adenosine receptor A3	Homo sapiens (human)
regulation of norepinephrine secretion	Adenosine receptor A3	Homo sapiens (human)
negative regulation of cell migration	Adenosine receptor A3	Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activity	Adenosine receptor A3	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Adenosine receptor A3	Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathway	Adenosine receptor A3	Homo sapiens (human)
synaptic transmission, dopaminergic	Adenosine receptor A2a	Homo sapiens (human)
response to amphetamine	Adenosine receptor A2a	Homo sapiens (human)
regulation of DNA-templated transcription	Adenosine receptor A2a	Homo sapiens (human)
phagocytosis	Adenosine receptor A2a	Homo sapiens (human)
apoptotic process	Adenosine receptor A2a	Homo sapiens (human)
inflammatory response	Adenosine receptor A2a	Homo sapiens (human)
cellular defense response	Adenosine receptor A2a	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
cell-cell signaling	Adenosine receptor A2a	Homo sapiens (human)
synaptic transmission, cholinergic	Adenosine receptor A2a	Homo sapiens (human)
central nervous system development	Adenosine receptor A2a	Homo sapiens (human)
blood coagulation	Adenosine receptor A2a	Homo sapiens (human)
sensory perception	Adenosine receptor A2a	Homo sapiens (human)
locomotory behavior	Adenosine receptor A2a	Homo sapiens (human)
blood circulation	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of cell population proliferation	Adenosine receptor A2a	Homo sapiens (human)
response to xenobiotic stimulus	Adenosine receptor A2a	Homo sapiens (human)
response to inorganic substance	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of glutamate secretion	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmission	Adenosine receptor A2a	Homo sapiens (human)
regulation of norepinephrine secretion	Adenosine receptor A2a	Homo sapiens (human)
response to purine-containing compound	Adenosine receptor A2a	Homo sapiens (human)
response to caffeine	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Adenosine receptor A2a	Homo sapiens (human)
synaptic transmission, glutamatergic	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of urine volume	Adenosine receptor A2a	Homo sapiens (human)
vasodilation	Adenosine receptor A2a	Homo sapiens (human)
eating behavior	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of vascular permeability	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of neuron apoptotic process	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleep	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of alpha-beta T cell activation	Adenosine receptor A2a	Homo sapiens (human)
astrocyte activation	Adenosine receptor A2a	Homo sapiens (human)
neuron projection morphogenesis	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of protein secretion	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of inflammatory response	Adenosine receptor A2a	Homo sapiens (human)
regulation of mitochondrial membrane potential	Adenosine receptor A2a	Homo sapiens (human)
membrane depolarization	Adenosine receptor A2a	Homo sapiens (human)
regulation of calcium ion transport	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Adenosine receptor A2a	Homo sapiens (human)
excitatory postsynaptic potential	Adenosine receptor A2a	Homo sapiens (human)
inhibitory postsynaptic potential	Adenosine receptor A2a	Homo sapiens (human)
prepulse inhibition	Adenosine receptor A2a	Homo sapiens (human)
apoptotic signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of long-term synaptic potentiation	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathway	Adenosine receptor A2b	Homo sapiens (human)
positive regulation of chronic inflammatory response to non-antigenic stimulus	Adenosine receptor A2b	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Adenosine receptor A2b	Homo sapiens (human)
activation of adenylate cyclase activity	Adenosine receptor A2b	Homo sapiens (human)
positive regulation of vascular endothelial growth factor production	Adenosine receptor A2b	Homo sapiens (human)
positive regulation of cGMP-mediated signaling	Adenosine receptor A2b	Homo sapiens (human)
cGMP-mediated signaling	Adenosine receptor A2b	Homo sapiens (human)
positive regulation of chemokine production	Adenosine receptor A2b	Homo sapiens (human)
positive regulation of interleukin-6 production	Adenosine receptor A2b	Homo sapiens (human)
mast cell degranulation	Adenosine receptor A2b	Homo sapiens (human)
positive regulation of mast cell degranulation	Adenosine receptor A2b	Homo sapiens (human)
relaxation of vascular associated smooth muscle	Adenosine receptor A2b	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Adenosine receptor A2b	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Adenosine receptor A2b	Homo sapiens (human)
vasodilation	Adenosine receptor A2b	Homo sapiens (human)
temperature homeostasis	Adenosine receptor A1	Homo sapiens (human)
response to hypoxia	Adenosine receptor A1	Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathway	Adenosine receptor A1	Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system process	Adenosine receptor A1	Homo sapiens (human)
negative regulation of acute inflammatory response	Adenosine receptor A1	Homo sapiens (human)
negative regulation of leukocyte migration	Adenosine receptor A1	Homo sapiens (human)
positive regulation of peptide secretion	Adenosine receptor A1	Homo sapiens (human)
positive regulation of systemic arterial blood pressure	Adenosine receptor A1	Homo sapiens (human)
negative regulation of systemic arterial blood pressure	Adenosine receptor A1	Homo sapiens (human)
regulation of glomerular filtration	Adenosine receptor A1	Homo sapiens (human)
protein targeting to membrane	Adenosine receptor A1	Homo sapiens (human)
phagocytosis	Adenosine receptor A1	Homo sapiens (human)
inflammatory response	Adenosine receptor A1	Homo sapiens (human)
signal transduction	Adenosine receptor A1	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Adenosine receptor A1	Homo sapiens (human)
cell-cell signaling	Adenosine receptor A1	Homo sapiens (human)
nervous system development	Adenosine receptor A1	Homo sapiens (human)
negative regulation of cell population proliferation	Adenosine receptor A1	Homo sapiens (human)
response to inorganic substance	Adenosine receptor A1	Homo sapiens (human)
negative regulation of glutamate secretion	Adenosine receptor A1	Homo sapiens (human)
response to purine-containing compound	Adenosine receptor A1	Homo sapiens (human)
lipid catabolic process	Adenosine receptor A1	Homo sapiens (human)
negative regulation of synaptic transmission, GABAergic	Adenosine receptor A1	Homo sapiens (human)
positive regulation of nucleoside transport	Adenosine receptor A1	Homo sapiens (human)
negative regulation of neurotrophin production	Adenosine receptor A1	Homo sapiens (human)
positive regulation of protein dephosphorylation	Adenosine receptor A1	Homo sapiens (human)
vasodilation	Adenosine receptor A1	Homo sapiens (human)
negative regulation of circadian sleep/wake cycle, non-REM sleep	Adenosine receptor A1	Homo sapiens (human)
negative regulation of apoptotic process	Adenosine receptor A1	Homo sapiens (human)
positive regulation of potassium ion transport	Adenosine receptor A1	Homo sapiens (human)
positive regulation of MAPK cascade	Adenosine receptor A1	Homo sapiens (human)
negative regulation of hormone secretion	Adenosine receptor A1	Homo sapiens (human)
cognition	Adenosine receptor A1	Homo sapiens (human)
leukocyte migration	Adenosine receptor A1	Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain	Adenosine receptor A1	Homo sapiens (human)
negative regulation of lipid catabolic process	Adenosine receptor A1	Homo sapiens (human)
positive regulation of lipid catabolic process	Adenosine receptor A1	Homo sapiens (human)
regulation of sensory perception of pain	Adenosine receptor A1	Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergic	Adenosine receptor A1	Homo sapiens (human)
fatty acid homeostasis	Adenosine receptor A1	Homo sapiens (human)
excitatory postsynaptic potential	Adenosine receptor A1	Homo sapiens (human)
long-term synaptic depression	Adenosine receptor A1	Homo sapiens (human)
mucus secretion	Adenosine receptor A1	Homo sapiens (human)
negative regulation of mucus secretion	Adenosine receptor A1	Homo sapiens (human)
triglyceride homeostasis	Adenosine receptor A1	Homo sapiens (human)
regulation of cardiac muscle cell contraction	Adenosine receptor A1	Homo sapiens (human)
apoptotic signaling pathway	Adenosine receptor A1	Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentration	Adenosine receptor A1	Homo sapiens (human)
negative regulation of long-term synaptic potentiation	Adenosine receptor A1	Homo sapiens (human)
negative regulation of long-term synaptic depression	Adenosine receptor A1	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Adenosine receptor A1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Process	via Protein(s)	Taxonomy
G protein-coupled adenosine receptor activity	Adenosine receptor A3	Homo sapiens (human)
G protein-coupled adenosine receptor activity	Adenosine receptor A2a	Homo sapiens (human)
protein binding	Adenosine receptor A2a	Homo sapiens (human)
calmodulin binding	Adenosine receptor A2a	Homo sapiens (human)
lipid binding	Adenosine receptor A2a	Homo sapiens (human)
enzyme binding	Adenosine receptor A2a	Homo sapiens (human)
type 5 metabotropic glutamate receptor binding	Adenosine receptor A2a	Homo sapiens (human)
identical protein binding	Adenosine receptor A2a	Homo sapiens (human)
protein-containing complex binding	Adenosine receptor A2a	Homo sapiens (human)
alpha-actinin binding	Adenosine receptor A2a	Homo sapiens (human)
G protein-coupled adenosine receptor activity	Adenosine receptor A2b	Homo sapiens (human)
protein binding	Adenosine receptor A2b	Homo sapiens (human)
G protein-coupled receptor activity	Adenosine receptor A2b	Homo sapiens (human)
G protein-coupled receptor binding	Adenosine receptor A1	Homo sapiens (human)
purine nucleoside binding	Adenosine receptor A1	Homo sapiens (human)
protein binding	Adenosine receptor A1	Homo sapiens (human)
heat shock protein binding	Adenosine receptor A1	Homo sapiens (human)
G-protein beta/gamma-subunit complex binding	Adenosine receptor A1	Homo sapiens (human)
heterotrimeric G-protein binding	Adenosine receptor A1	Homo sapiens (human)
protein heterodimerization activity	Adenosine receptor A1	Homo sapiens (human)
G protein-coupled adenosine receptor activity	Adenosine receptor A1	Homo sapiens (human)
G protein-coupled adenosine receptor activity	Adenosine receptor A2a	Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Process	via Protein(s)	Taxonomy
plasma membrane	Adenosine receptor A3	Homo sapiens (human)
presynaptic membrane	Adenosine receptor A3	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Adenosine receptor A3	Homo sapiens (human)
dendrite	Adenosine receptor A3	Homo sapiens (human)
plasma membrane	Adenosine receptor A3	Homo sapiens (human)
synapse	Adenosine receptor A3	Homo sapiens (human)
plasma membrane	Adenosine receptor A2a	Homo sapiens (human)
intermediate filament	Adenosine receptor A2a	Homo sapiens (human)
plasma membrane	Adenosine receptor A2a	Homo sapiens (human)
membrane	Adenosine receptor A2a	Homo sapiens (human)
dendrite	Adenosine receptor A2a	Homo sapiens (human)
axolemma	Adenosine receptor A2a	Homo sapiens (human)
asymmetric synapse	Adenosine receptor A2a	Homo sapiens (human)
presynaptic membrane	Adenosine receptor A2a	Homo sapiens (human)
neuronal cell body	Adenosine receptor A2a	Homo sapiens (human)
postsynaptic membrane	Adenosine receptor A2a	Homo sapiens (human)
presynaptic active zone	Adenosine receptor A2a	Homo sapiens (human)
glutamatergic synapse	Adenosine receptor A2a	Homo sapiens (human)
plasma membrane	Adenosine receptor A2b	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Adenosine receptor A2b	Homo sapiens (human)
presynapse	Adenosine receptor A2b	Homo sapiens (human)
glutamatergic synapse	Adenosine receptor A2b	Homo sapiens (human)
plasma membrane	Adenosine receptor A2b	Homo sapiens (human)
plasma membrane	Adenosine receptor A1	Homo sapiens (human)
plasma membrane	Adenosine receptor A1	Homo sapiens (human)
basolateral plasma membrane	Adenosine receptor A1	Homo sapiens (human)
axolemma	Adenosine receptor A1	Homo sapiens (human)
asymmetric synapse	Adenosine receptor A1	Homo sapiens (human)
presynaptic membrane	Adenosine receptor A1	Homo sapiens (human)
neuronal cell body	Adenosine receptor A1	Homo sapiens (human)
terminal bouton	Adenosine receptor A1	Homo sapiens (human)
dendritic spine	Adenosine receptor A1	Homo sapiens (human)
calyx of Held	Adenosine receptor A1	Homo sapiens (human)
postsynaptic membrane	Adenosine receptor A1	Homo sapiens (human)
presynaptic active zone	Adenosine receptor A1	Homo sapiens (human)
synapse	Adenosine receptor A1	Homo sapiens (human)
dendrite	Adenosine receptor A1	Homo sapiens (human)
Golgi membrane	Adenosine receptor A2a	Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (56)

Assay ID	Title	Year	Journal	Article
AID706388	Displacement of [3H]CGS21680 from human recombinant adenosine A2A receptor expressed in CHO cells after 60 mins by gamma counter	2012	Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12	Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.
AID175310	Enhancement of coronary flow (A2 response) in isolated rat heart preparation	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.
AID30496	Molar potency ratio (MPR) against adenosine A2 receptor of canine coronary artery	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	Dog coronary artery adenosine receptor: structure of the N6-aryl subregion.
AID30491	Binding affinity against A2 adenosine receptor	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	Dog coronary artery adenosine receptor: structure of the N6-aryl subregion.
AID30495	Association constant against A2 adenosine receptor	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	Dog coronary artery adenosine receptor: structure of the N6-aryl subregion.
AID706383	Selectivity ratio of Ki for rat adenosine A1 receptor to Ki for rat adenosine A3 receptor expressed in CHO cells	2012	Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12	Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.
AID706382	Selectivity ratio of Ki for human recombinant adenosine A1 receptor to Ki for human recombinant adenosine A3 receptor expressed in CHO cells	2012	Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12	Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.
AID175313	Reduction of heart rate (A1 response) in isolated rat heart preparation	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.
AID1694570	Displacement of [3H]CGS21680 from recombinant human A2AR measured after 60 mins by liquid scintillation counting method	2021	ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3	Biological Evaluation of 5'-(
AID239053	Inhibition of [125I]AB-MECA binding to rat Adenosine A3 receptor expressed in CHO cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.
AID155531	Inhibition of Trypanosoma brucei phosphoglycerate kinase (PGK); inactive at 4 mM	2000	Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22	Adenosine analogues as inhibitors of Trypanosoma brucei phosphoglycerate kinase: elucidation of a novel binding mode for a 2-amino-N(6)-substituted adenosine.
AID1694562	Antimigratory activity in human MDA-MB-231 cells assessed as wound closure at 2.5 uM after 48 hrs by scratch wound healing assay (Rvb = 93 %)	2021	ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3	Biological Evaluation of 5'-(
AID177479	Effect on Ataxia(ATX) in rat was measured as ED50 by perorally administration of compound.	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.
AID1694548	Displacement of FITC-geldanamycin from GRP94 (unknown origin) at 50 uM after 24 hrs by fluorescence polarization assay relative to control	2021	ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3	Biological Evaluation of 5'-(
AID25506	Index of hydrophobicity (k')	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	Dog coronary artery adenosine receptor: structure of the N6-aryl subregion.
AID1694557	Antimigratory activity in human A549 cells assessed as wound closure at 2.5 uM after 24 hrs by scratch wound healing assay (Rvb = 59 %)	2021	ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3	Biological Evaluation of 5'-(
AID1694569	Displacement of [3H]R-PIA from recombinant human A1AR measured after 60 mins by liquid scintillation counting method	2021	ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3	Biological Evaluation of 5'-(
AID232472	Selectivity ratio for A1 receptor to that of A2 receptor in vitro in rat tissues	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.
AID1694567	Antimigratory activity in human MDA-MB-231 cells assessed as rate of wound closure at 20 uM after 24 hrs by scratch wound healing assay	2021	ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3	Biological Evaluation of 5'-(
AID1694558	Antimigratory activity in human A549 cells assessed as wound closure at 2.5 uM after 36 hrs by scratch wound healing assay (Rvb = 88 %)	2021	ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3	Biological Evaluation of 5'-(
AID32503	Inhibition of binding of [3H]N6-cyclohexyladenosine to adenosine A1 receptor of rat whole brain membranes.	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.
AID32195	Binding affinity towards adenosine A1 receptor on rat whole brain membrane using [3H]N6-cyclohexyladenosine	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.
AID239011	Inhibition of [3H]R-PIA binding to human Adenosine A1 receptor expressed in CHO cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.
AID1694571	Displacement of [125I]-AB-MECA from human A3AR expressed in CHO cells measured after 60 mins by liquid scintillation counting method	2021	ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3	Biological Evaluation of 5'-(
AID251590	Relative activation of human Adenosine A3 receptor expressed in CHO cells at 10 uM treatment compared to 10 uM Cl-IB-MECA	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.
AID706386	Displacement of [3H]CCPA from human recombinant adenosine A1 receptor expressed in CHO cells after 60 mins by gamma counter	2012	Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12	Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.
AID1694549	Displacement of FITC-geldanamycin from HSP90alpha (unknown origin) at 50 uM after 24 hrs by fluorescence polarization assay relative to control	2021	ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3	Biological Evaluation of 5'-(
AID706384	Displacement of [125I]I-AB-MECA from human recombinant adenosine A3 receptor expressed in CHO cells after 60 mins by gamma counter	2012	Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12	Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.
AID1694561	Antimigratory activity in human MDA-MB-231 cells assessed as wound closure at 2.5 uM after 24 hrs by scratch wound healing assay (Rvb = 64 %)	2021	ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3	Biological Evaluation of 5'-(
AID706387	Displacement of [3H]CCPA from rat adenosine A1 receptor expressed in CHO cells after 60 mins by gamma counter	2012	Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12	Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.
AID231269	Ratio of binding affinity against A2 and A1 receptors	1988	Journal of medicinal chemistry, Jul, Volume: 31, Issue:7	N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor.
AID1694568	Antimigratory activity in human MDA-MB-231 cells assessed as rate of wound closure at 20 uM after 48 hrs by scratch wound healing assay	2021	ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3	Biological Evaluation of 5'-(
AID33440	Binding affinity at adenosine A2 receptor from rat striatal membranes by [3H]NECA displacement.	1988	Journal of medicinal chemistry, Jul, Volume: 31, Issue:7	N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor.
AID706381	Selectivity ratio of Ki for rat adenosine A2A receptor to Ki for rat adenosine A3 receptor expressed in CHO cells	2012	Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12	Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.
AID177487	Effect on Motor activity(MA) in rat was measured as ED50 by perorally administration of compound.	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.
AID647885	Binding affinity to A2A adenosine receptor	2012	Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1	Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A₂A adenosine receptor.
AID33567	Binding affinity to A2 adenosine receptor in rat striatal membranes by [3H]NECA (1-(6-amino-9H-purin-9-yl)-1-deoxy-N-ethyl-beta-D-ribofuranuronamide) displacement.	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.
AID131362	Effect on Ataxia in mouse following i.p. administration.	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.
AID229799	Ratio of Ki at adenosine A2 and A1 receptors	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.
AID239092	Inhibition of [125I]-AB-MECA binding to human Adenosine A3 receptor expressed in CHO cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.
AID33588	Binding affinity towards adenosine A2 receptor on rat striatal membrane using [3H]NECA as radioligand	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	N6-(arylalkyl)adenosines. Identification of N6-(9-fluorenylmethyl)adenosine as a highly potent agonist for the adenosine A2 receptor.
AID706389	Displacement of [3H]CGS21680 from rat adenosine A2A receptor expressed in CHO cells after 60 mins by gamma counter	2012	Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12	Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.
AID177488	Effect on Sidman conditioned avoidance in rat.	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.
AID31866	Binding affinity at adenosine A1 receptor from rat brain membranes by [3H]N6-cyclohexyladenosine displacement.	1988	Journal of medicinal chemistry, Jul, Volume: 31, Issue:7	N6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor.
AID32015	Binding affinity to adenosine A1 receptor in rat whole brain membranes by [3H]N6-cyclohexyladenosine displacement.	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.
AID33746	Binding affinity against adenosine A2 receptor using [3H]- NECA as radioligand	1992	Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3	Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID706385	Displacement of [125I]I-AB-MECA from human rat adenosine A3 receptor expressed in CHO cells after 60 mins by gamma counter	2012	Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12	Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.
AID33752	Ratio of A2 to A1.	1992	Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3	Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID706380	Selectivity ratio of Ki for human recombinant adenosine A2A receptor to Ki for human recombinant adenosine A3 receptor expressed in CHO cells	2012	Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12	Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.
AID239113	Inhibition of [3H]-CGS- 21680 binding to human Adenosine A2A receptor expressed in CHO cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.
AID1694572	Agonist activity at recombinant human A2BAR expressed in CHO cells assessed as stimulation of cAMP formation preincubated for 30 mins in presence of rolipram and adenosine deaminase followed by compound addition and measured after 20 mins by alphascreen c	2021	ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3	Biological Evaluation of 5'-(
AID251589	Relative activation of human Adenosine A2B receptor at 10 uM treatment compared to 10 uM Cl-IB-MECA	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.
AID706377	Antagonist activity at human adenosine A3 receptor expressed in CHO cells assessed as blockade of Cl-IB-MECA-mediated inhibition of forskolin-stimulated [3H]cAMP accumulation by scintillation counter	2012	Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12	Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.
AID131363	Effect on Motor activity in mouse following i.p. administration.	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.
AID32177	Binding affinity against adenosine A1 receptor using [3H]-CHA or [3H]PIA as radioligand	1992	Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3	Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID33733	Inhibition of binding of [3H]NECA to adenosine A2 receptor of rat striatal membranes.	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	5 (41.67)	18.7374
1990's	2 (16.67)	18.2507
2000's	2 (16.67)	29.6817
2010's	2 (16.67)	24.3611
2020's	1 (8.33)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.16 (24.57)
Research Supply Index	2.56 (2.92)
Research Growth Index	4.73 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.16)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (16.67%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (83.33%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
1,3-dipropyl-8-cyclopentylxanthine DPCPX : An oxopurine that is 7H-xanthine substituted at positions 1 and 3 by propyl groups and at position 8 by a cyclohexyl group.	3.08	1	oxopurine	adenosine A1 receptor antagonist; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
8-(4-sulfophenyl)theophylline 8-(4-sulfophenyl)theophylline: adenosine antagonist	3.08	1
8-cyclopentyl-1,3-dimethylxanthine 8-cyclopentyl-1,3-dimethylxanthine: prolongs epileptic seizures in rats	3.08	1	oxopurine
8-phenyltheophylline 8-phenyltheophylline: purinergic P1 receptor antagonist	3.08	1
theophylline [no description available]	3.08	1	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
caffeine [no description available]	3.08	1	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
cgs 15943 9-chloro-2-(2-furyl)-(1,2,4)triazolo(1,5-c)quinazolin-5-imine: non-xanthine triazoloquinazoline adenosine antagonist. CGS 15943 : A member of the class of triazoloquinazolines that is [1,2,4]triazolo[1,5-c]quinazoline substited at positions 2, 5 and 9 by furan-2-yl, amino and chloro groups respectively. A potent antagonist at adenosine A1 and adenosine A2A receptors.	3.08	1	aromatic amine; biaryl; furans; organochlorine compound; primary amino compound; quinazolines; triazoloquinazoline	adenosine A1 receptor antagonist; adenosine A2A receptor antagonist; antineoplastic agent; central nervous system stimulant
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	1.97	1	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
thioridazine Thioridazine: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.. thioridazine : A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position.	1.97	1	phenothiazines; piperidines	alpha-adrenergic antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine 8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine: adenosine receptor antagonist	3.08	1
2-chloroadenosine 5-chloroformycin A: structure given in first source	4.01	4	purine nucleoside
hyaluronoglucosaminidase kinetin riboside: preferentially induces apoptosis by modulating Bcl-2 family proteins and caspase-3 in cancer cells; structure in first source	2.38	2	purine nucleoside
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	3.25	6	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
rolofylline rolofylline: selective antagonist for adenosine receptors; a cardiovascular agent	3.08	1	oxopurine
isoguanosine [no description available]	1.97	1	purine nucleoside
metrifudil [no description available]	2.68	3
2-aminoadenosine [no description available]	2	1	purine nucleoside
n(6)-benzyladenosine N(6)-benzyladenosine: RN given refers to parent cpd	3.07	5
1,3-dipropyl-8-(2-amino-4-chlorophenyl)xanthine [no description available]	3.08	1
phenylisopropyladenosine [no description available]	4.32	6	aromatic amine; benzenes; hydrocarbyladenosine; purine nucleoside; secondary amino compound	adenosine A1 receptor agonist; neuroprotective agent
n-allyladenosine [no description available]	2	1	purine nucleoside
adenosine-5'-carboxylic acid [no description available]	2.31	1	purine nucleoside
adenosine 5'-carboxamide adenosine 5'-carboxamide: structure	2.31	1
5'-n-methylcarboxamideadenosine 5'-N-methylcarboxamideadenosine: RN given refers to (beta-D)-isomer	2.31	1
3,7-dimethyl-1-propargylxanthine 3,7-dimethyl-1-propargylxanthine: potent & selective in vivo antagonist of adenosine analogs	3.08	1
n(6)-phenyladenosine [no description available]	3.76	3	purine nucleoside
n-methyladenosine N-methyladenosine: is a inhibitor of cell differentiation. N(6)-methyladenosine : A methyladenosine compound with one methyl group attached to N(6) of the adenine nucleobase.	2.74	3	methyladenosine
n-(1-methyl-2-phenylethyl)adenosine N-(1-methyl-2-phenylethyl)adenosine: RN given refers to cpd without isomeric designation; structure given in first source	1.97	1
n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine: structure given in first source; a selective A(3) adenosine receptor agonist. 3-iodobenzyl-5'-N-methylcarboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by N-ethylcarboxamido and one of the hydrogens of the exocyclic amino function is substituted by a 3-iodobenzyl group.	3.55	2	adenosines; monocarboxylic acid amide; organoiodine compound	adenosine A3 receptor agonist
2-chloro-n(6)cyclopentyladenosine 2-chloro-N(6)cyclopentyladenosine: highly selective agonist at A1 adenosine receptors	3.08	1
cp 66713 CP 66713: adenosine receptor antagonist; structure given in first source	3.08	1
adenosine amine congener adenosine amine congener: a highly potent & selective adenosine A1 receptor agonist	3.08	1
8-(4-carboxymethyloxy)phenyl-1,3-dipropylxanthine 8-(4-carboxymethyloxy)phenyl-1,3-dipropylxanthine: used to localize adenosine receptors in the brain	3.08	1
8-(dicyclopropylmethyl)-1,3-dipropylxanthine 8-(dicyclopropylmethyl)-1,3-dipropylxanthine: selective A1 adenosine receptor antagonist; structure given in first source	3.08	1
kfm 19 KFM 19: a potential cognitive enhancer and a selective adenosine A1 receptor antagonist	3.08	1
2-(1-octynyl)adenosine YT 146: an adenosine receptor agonist; structure given in first source	3.08	1
regadenoson [no description available]	2.07	1	purine nucleoside
8-cyclohexylcaffeine [no description available]	3.08	1
mrs 1067 3,6-dichloro-2'-isopropyloxy-4'-methylflavone: structure in first source	3.17	1
mrs 1220 9-chloro-2-(2-furyl)-5-phenylacetylamino(1,2,4)triazolo(1,5-c)quinazoline: structure in first source	3.17	1	quinazolines
adenosine 5'-phosphoramidate adenosine 5'-phosphoramidate : The phosphoramadite analogue of AMP.	2.31	1	organic phosphoramidate	Mycoplasma genitalium metabolite
adenosine-5'-(n-ethylcarboxamide) Adenosine-5'-(N-ethylcarboxamide): A stable adenosine A1 and A2 receptor agonist. Experimentally, it inhibits cAMP and cGMP phosphodiesterase activity.. N-ethyl-5'-carboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by an N-ethylcarboxamido group.	4.2	5	adenosines; monocarboxylic acid amide	adenosine A1 receptor agonist; adenosine A2A receptor agonist; antineoplastic agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
n(6)-cyclopentyladenosine [no description available]	4.17	5
2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide: structure given in first source	3.55	2
adenosine-5'-(N-propyl)carboxamide adenosine-5'-(N-propyl)carboxamide : A monocarboxylic acid amide that is the propyl amide of adenosine 5'-carboxylic acid.	2.31	1	adenosines; monocarboxylic acid amide
2-((2-aminoethylamino)carbonylethylphenylethylamino)-5'-n-ethylcarboxamidoadenosine 2-((2-aminoethylamino)carbonylethylphenylethylamino)-5'-N-ethylcarboxamidoadenosine: structure given in first source	3.51	2
2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine: A2 adenosine receptor agonist; structure given in first source. CGS-21680 : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by N-ethylcarboxamido and the hydrogen at position 2 on the adenine is replaced by a 4-(2-carboxyethyl)phenethylamino group.	3.51	2	adenosines; dicarboxylic acid monoamide; monocarboxylic acid	adenosine A2A receptor agonist; anti-inflammatory agent
n-(1-methyl-2-phenylethyl)adenosine, (s)-isomer [no description available]	1.97	1
cv 1808 2-phenylaminoadenosine: has coronary & cardiohemodynamic effects	3.99	4	purine nucleoside
1-aminoadenosine 1-aminoadenosine: structure	2.31	1
binodenoson [no description available]	2.07	1
atl 146e BMS-068645: structure in first source	2.07	1
5'-amino-5'-deoxyadenosine [no description available]	2.31	1
uk-432097 UK-432097: a highly potent and selective agonist and drug candidate for chronic obstructive pulmonary disease (COPD) treatment; structure in first source	2.07	1
n(6)-cyclohexyladenosine N(6)-cyclohexyladenosine: structure given in first source; receptors, purinergic P1 agonist	3.77	3
2-(2-(4-chlorophenyl)ethoxy)adenosine 2-(2-(4-chlorophenyl)ethoxy)adenosine: a adenosine A2A receptor agonist	2.07	1
vuf 8504 [no description available]	3.17	1
cgs 24012 CGS 24012: adenosine agonist with both high affinity & selectivity for the adenosine A2 receptor	3.76	3
n-cyclopropyl adenosine-5'-carboxamide [no description available]	2.31	1
mrs 3558 [no description available]	3.55	2
atl 313 ATL 313: A2A adenosine receptor agonist	2.07	1
luf 6000 [no description available]	3.17	1
psb 11 [no description available]	3.17	1

Condition	Indicated	Relationship Strength	Studies	Trials
Ataxia Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.	0	1.97	1	0
Disease A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.	0	2.99	1	0

chemdatabank.com